Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cell

• Publication date

  2009-07-23

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/j.cell.2009.04.056PMID 19632176PMCID PMC2726827
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription.

  2008influential reference
• SOX9 is expressed in human fetal prostate epithelium and enhances prostate cancer invasion.

  2008cited by this paper
• Systematic evaluation of variability in ChIP-chip experiments using predefined DNA targets.

  2008cited by this paper
• Methylation of lysine 4 on histone H3: intricacy of writing and reading a single epigenetic mark.

  2007cited by this paper
• Ubiquitination by the anaphase-promoting complex drives spindle checkpoint inactivation

  2007influential reference
• High-resolution profiling of histone methylations in the human genome.

  2007cited by this paper
• Chromatin modifications and their function.

  2007cited by this paper
• Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome

  2007influential reference
• Quantitative analysis of chromosome conformation capture assays (3C-qPCR)

  2007cited by this paper
• Integrative molecular concept modeling of prostate cancer progression

  2007cited by this paper
• The Complex Role of AR Signaling After Cytotoxic Insult: Implications for Cell Cycle Based Chemotherapeutics

  2007influential reference
• A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth.

  2007cited by this paper
• Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.

  2006influential reference
• Expression and effect of inhibition of the ubiquitin-conjugating enzyme E2C on esophageal adenocarcinoma.

  2006cited by this paper
• Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer.

  2006influential reference
• Model-based analysis of tiling-arrays for ChIP-chip

  2006cited by this paper
• Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1.

  2005cited by this paper
• Genomic maps and comparative analysis of histone modifications in human and mouse.

  2005cited by this paper
• UbcH10 overexpression may represent a marker of anaplastic thyroid carcinomas

  2005cited by this paper
• Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data

  2005cited by this paper
• Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking.

  2005influential reference
• Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression.

  2005influential reference
• Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis.

  2005cited by this paper
• Androgen receptor down regulation by small interference RNA induces cell growth inhibition in androgen sensitive as well as in androgen independent prostate cancer cells.

  2005cited by this paper
• Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer.

  2004cited by this paper
• Overexpression, genomic amplification and therapeutic potential of inhibiting the UbcH10 ubiquitin conjugase in human carcinomas of diverse anatomic origin

  2004cited by this paper
• Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.

  2004cited by this paper
• Androgen receptor in prostate cancer.

  2004cited by this paper
• Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.

  2004cited by this paper
• Coactivator AIB1 links estrogen receptor transcriptional activity and stability.

  2004cited by this paper
• Molecular determinants of resistance to antiandrogen therapy

  2004cited by this paper
• Mechanisms of androgen-refractory prostate cancer.

  2004influential reference
• Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

  2003cited by this paper
• Phosphorylation of serine 10 in histone H3, what for?

  2003cited by this paper
• alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.

  2002cited by this paper
• Formation of the androgen receptor transcription complex.

  2002cited by this paper
• A Coregulatory Role for the TRAP-Mediator Complex in Androgen Receptor-mediated Gene Expression*

  2002influential reference
• The development of androgen-independent prostate cancer

  2001influential reference
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group.

  2000cited by this paper
• Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials

  2000cited by this paper
• LNCaP progression model of human prostate cancer: Androgen‐independence and osseous metastasis

  2000influential reference
• Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy.

  1999influential reference
• Switch from antagonist to agonist of the androgen receptor blocker bicalutamide is associated with prostate tumour progression in a new model system

  1999influential reference
• Androgen receptor-associated protein complex binds upstream of the androgen-responsive elements in the promoters of human prostate-specific antigen and kallikrein 2 genes.

  1997influential reference
• The androgen receptor in prostate cancer.

  1996influential reference
• Prostate-specific Antigen Expression Is Regulated by an Upstream Enhancer (*)

  1996influential reference
• Cyclin A-associated kinase activity is rate limiting for entrance into S phase and is negatively regulated in G1 by p27Kip1

  1995cited by this paper
• The nuclear receptor superfamily: the second decade.

  1995cited by this paper
• Cyclin A is required for the onset of DNA replication in mammalian fibroblasts.

  1991cited by this paper
• Chromatin Modifications and Their Function

  year unknowncited by this paper

• Mechanistic Roles of Androgen and Estrogen in Aging and Age-Related Diseases

  2026cites this paper
• Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology

  2025cites this paper
• EHMT2‐mediated R‐loop formation promotes the malignant progression of prostate cancer via activating Aurora B

  2025cites this paper
• Evolving roles for the androgen receptor and its protein interactome in castration-resistant prostate cancer

  2025cites this paper
• Protein disulfide isomerases regulate androgen receptor stability and promote prostate cancer cell growth and survival.

  2025cites this paper
• Liquiritigenin protects against cadmium-induced testis damage in mice by inhibiting apoptosis and activating androgen receptor.

  2025cites this paper
• NASP implication in the androgen receptor associated with castration resistance in prostate cancer

  2025influential citation
• Decoding the germline genetic architecture of prostate cancer at a single cell resolution

  2025cites this paper
• Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617

  2025cites this paper
• Progress of targeted FOX family therapy in ovarian cancer

  2025cites this paper
• JARID1D-dependent androgen receptor and JunD signaling activation of osteoclast differentiation inhibits prostate cancer bone metastasis through demethylating H3K4

  2025cites this paper
• Targeting epigenetic effects of androgen-androgen receptor signaling in prostate cancer.

  2025cites this paper
• Understanding Enzalutamide‐Resistance Based on a Functional Single‐Cell Approach

  2025cites this paper
• Targeting FOXA1 and FOXA2 Disrupts the Lineage-Specific Oncogenic Output Program in Prostate Cancer

  2025cites this paper
• SNP rs9364554 Modulates Androgen Receptor Binding and Drug Response in Prostate Cancer

  2025cites this paper
• Disrupting the interaction between androgen receptor and its coregulator WDR77 delays the growth of treatment-resistant prostate cancer.

  2025cites this paper
• Analysis of miRNA expression profiles during spermatogenesis of plateau zokor (Eospalax baileyi) under androgen antagonism treatment.

  2025cites this paper
• Assessment of Genotoxicity in Females with Polycystic Ovary Syndrome: Insights from the Ahmedabad Region

  2025cites this paper
• Alterations in AR-FOXA1 signaling in prostate cancer progression and therapeutic resistance.

  2025cites this paper
• Emerging therapies to overcome antiandrogen resistance and beyond in lethal prostate cancer.

  2025cites this paper
• Coregulators determine androgen receptor activity in prostate cancer

  2025cites this paper
• Regulation of gene expression by FOXA1

  2025cites this paper
• Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer

  2025cites this paper
• Androgen Receptor Signalling in Prostate Cancer: Mechanisms of Resistance to Endocrine Therapies

  2025cites this paper
• AR to GR switch modulates differential TDO2-Kyn-AhR signalling to promote the survival and recurrence of treatment-induced dormant cells in prostate cancer

  2025cites this paper
• Nuclear receptors in cancer: Unveiling theranostic potentials and innovative therapeutic strategies.

  2025cites this paper
• Epigenetic Preparation of Future Gene Induction Kinetics.

  2025cites this paper
• BCL2 drives castration resistance in castration-sensitive prostate cancer by orchestrating reciprocal crosstalk between oncogenic pathways

  2025cites this paper
• USP54 is a potential therapeutic target in castration-resistant prostate cancer

  2024cites this paper
• Epigenome-wide impact of MAT2A sustains the androgen-indifferent state and confers synthetic vulnerability in ERG fusion-positive prostate cancer

  2024influential citation
• Subtype Transdifferentiation in Human Cancer: The Power of Tissue Plasticity in Tumor Progression

  2024cites this paper
• Protective effects of adipose-derived stem cells against testicular injury induced after ischemia–reperfusion by regulating autophagy

  2024cites this paper
• Ubiquitination-Binding Enzyme 2C is Associated with Cancer Development and Prognosis and is a Potential Therapeutic Target

  2024cites this paper
• Carotenoids as modulators of the PI3K/Akt/mTOR pathway: innovative strategies in cancer therapy

  2024cites this paper
• Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers

  2024cites this paper
• Curcumin blunts epithelial-mesenchymal transition to alleviate invasion and metastasis of prostate cancer through the JARID1D demethylation

  2024cites this paper
• Tackling exosome and nuclear receptor interaction: an emerging paradigm in the treatment of chronic diseases

  2024cites this paper
• Perilous consequences of chemotherapy induced alopecia in afflicted cancer survivors: a comprehensive state of the art review

  2024cites this paper
• Editorial Comment on Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries

  2024cites this paper
• Exploring androgen receptor signaling pathway in prostate cancer: A path to new discoveries

  2024cites this paper
• Dihydrotestosterone Enhances MICA-Mediated Immune Responses to Epstein–Barr Virus-Associated Gastric Carcinoma

  2024cites this paper
• AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer

  2024cites this paper
• AR-V7 expression facilitates accelerated G2/M phase transition in castration-resistant prostate cancer.

  2024cites this paper
• Context-specific targeting of the androgen receptor in prostate cancer

  2024cites this paper
• AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer

  2024cites this paper
• An in silico procedure for generating protein-mediated chromatin interaction data and comparison of significant interaction calling methods

  2024cites this paper
• Curcumin inhibits prostate cancer by upregulating miR‐483‐3p and inhibiting UBE2C

  2024cites this paper
• WNT1-inducible signaling pathway protein 1 activation through C-X-C motif chemokine ligand 5/C-X-C chemokine receptor type 2/leukemia inhibitory factor/leukemia inhibitory factor receptor signaling promotes immunosuppression and neuroendocrine differentiation in prostate cancer

  2024cites this paper
• Zn2+-interference and H2S-mediated gas therapy based on ZnS-tannic acid nanoparticles synergistic enhancement of cell apoptosis for specific treatment of prostate cancer.

  2023cites this paper
• RB1-deficient prostate tumor growth and metastasis are vulnerable to ferroptosis induction via the E2F/ACSL4 axis

  2023cites this paper
• The epigenetic function of androgen receptor in prostate cancer progression

  2023cites this paper
• Enhancer profiling identifies epigenetic markers of endocrine resistance and reveals therapeutic options for metastatic castration-resistant prostate cancer patients

  2023cites this paper
• TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer

  2023cites this paper
• Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer

  2023cites this paper
• Synthesis, Solid State Structure, and Cytotoxic Activity of a Complex Dimer of Yttrium with Anthranilic Acid against Cancer Cells

  2023cites this paper
• Estrogens drive the endoplasmic reticulum-associated degradation and promote proto-oncogene c-Myc expression in prostate cancer cells by androgen receptor/estrogen receptor signaling

  2023cites this paper
• Biochemistry and pathophysiology of the Transient Potential Receptor Vanilloid 6 (TRPV6) calcium channel.

  2023cites this paper
• Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients

  2023cites this paper
• The correlation between the expression of ubiquitin-conjugating enzyme 2C and prostate cancer prognosis

  2023cites this paper
• Bioinformatics and In silico approaches to identify novel biomarkers and key pathways for cancers that are linked to the progression of female infertility: A comprehensive approach for drug discovery

  2023cites this paper
• Clinical impact of androgen receptor-suppressing miR-146b expression in papillary thyroid cancer aggressiveness.

  2023cites this paper
• Identification of androgen response‐related lncRNAs in prostate cancer

  2023cites this paper
• Androgen Receptor/AP-1 Activates UGT2B15 Transcription to Promote Esophageal Squamous Cell Carcinoma Invasion

  2023cites this paper
• Role of the pioneer transcription factor GATA2 in health and disease

  2023cites this paper
• Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer

  2023cites this paper
• Deoxynortryptoquivaline: A unique antiprostate cancer agent

  2023cites this paper
• Targeting the Androgen Signaling Axis in Prostate Cancer.

  2023cites this paper
• Etiology of super-enhancer reprogramming and activation in cancer

  2023cites this paper
• Newly developed preclinical models reveal broad‐spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide

  2023cites this paper
• Feasibility of apalutamide combined with androgen deprivation therapy and short-course low-dose prednisone in treating metastatic hormone-sensitive prostate cancer: a pilot randomized controlled trial

  2023cites this paper
• NSD2 maintains lineage plasticity and castration-resistance in neuroendocrine prostate cancer

  2023cites this paper
• A multivalent peptoid conjugate modulates androgen receptor transcriptional activity to inhibit therapy-resistant prostate cancer.

  2023cites this paper
• Fibroblast activation protein-alpha knockdown suppresses prostate cancer cell invasion and proliferation.

  2022cites this paper
• Endoplasmic reticulum stress inhibits AR expression via the PERK/eIF2α/ATF4 pathway in luminal androgen receptor triple-negative breast cancer and prostate cancer

  2022cites this paper
• Therapeutic potential of p53 reactivation in prostate cancer: Strategies and opportunities.

  2022cites this paper
• Impact of Androgen Receptor Activity on Prostate-Specific Membrane Antigen Expression in Prostate Cancer Cells

  2022cites this paper
• [Recent advances in the sex steroid hormone action involved in the development of dementia and frailty].

  2022cites this paper
• Plk1 Inhibitors and Abiraterone Synergistically Disrupt Mitosis and Kill Cancer Cells of Disparate Origin Independently of Androgen Receptor Signaling.

  2022cites this paper
• Prostate cancer small extracellular vesicles participate in androgen-independent transformation of prostate cancer by transferring let-7a-5p

  2022cites this paper
• Androgen Receptor-Mediated Transcription in Prostate Cancer

  2022cites this paper
• Estrogen-Inducible LncRNA BNAT1 Functions as a Modulator for Estrogen Receptor Signaling in Endocrine-Resistant Breast Cancer Cells

  2022cites this paper
• Synthesis, X-ray structure and anticancer activity evaluation of a binuclear La(III) complex with anthranilic acid

  2022cites this paper
• Binuclear Cu(II) complex based on N-acetylanthranilic acid induces significant cytotoxic effect on three cancer cell lines

  2022cites this paper
• The testosterone paradox of advanced prostate cancer: mechanistic insights and clinical implications

  2022cites this paper
• The METTL3 RNA Methyltransferase Regulates Transcriptional Networks in Prostate Cancer

  2022influential citation
• Homing in on a moving target: Androgen Receptor cistromic plasticity in prostate cancer.

  2022cites this paper
• Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2

  2022cites this paper
• Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer

  2022cites this paper
• Prostate Cancer Epigenetic Plasticity and Enhancer Heterogeneity: Molecular Causes, Consequences and Clinical Implications.

  2022cites this paper
• AR Structural Variants and Prostate Cancer.

  2022cites this paper
• Combinatorial approaches of nanotherapeutics for inflammatory pathway targeted therapy of prostate cancer.

  2022cites this paper
• Androgen Receptor Splice Variants Contribute to the Upregulation of DNA Repair in Prostate Cancer

  2022cites this paper
• FBXO42 facilitates Notch signaling activation and global chromatin relaxation by promoting K63-linked polyubiquitination of RBPJ

  2022cites this paper
• Targeting phase separation on enhancers induced by transcription factor complex formations as a new strategy for treating drug-resistant cancers

  2022cites this paper
• Androgen Metabolism and Response in Prostate Cancer Anti-Androgen Therapy Resistance

  2022cites this paper
• Identification and Validation of Three Hub Genes Involved in Cell Proliferation and Prognosis of Castration-Resistant Prostate Cancer

  2022cites this paper
• FOXA1 in prostate cancer

  2022cites this paper
• The regulatory role of pioneer factors during cardiovascular lineage specification – A mini review

  2022cites this paper
• Stem Cells as Target for Prostate cancer Therapy: Opportunities and Challenges

  2022cites this paper
• Androgens drive sexual dimorphism in liver metastasis by promoting hepatic accumulation of neutrophils.

  2022cites this paper